However, recent developments—such as the 2018 World Health Assembly recommendation to prioritize a vaccine to combat RHD and the establishment of SAVAC on the heels of the WHO-produced vaccine development roadmap—have reenergized the initiative: eight candidates are currently on a product development track, including four M protein–based candidates and four candidates designed around non–M protein antigens. Here, MYOM2 is linked to rheumatic heart disease.